Showing results (51-60 of 443) with videos related to
Sort By:
Pageof 45
Annals of the American Thoracic Society|November 14, 2023
Neighborhood Health and Outcomes in Idiopathic Pulmonary FibrosisAlison M DeDent, Harold R Collard, Neeta ThakurThorax|March 20, 2012
Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosisLuca Richeldi, Christopher J Ryerson, Joyce S Lee, et al.Expert Opinion on Emerging Drugs|May 17, 2021
Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trialsGiacomo Sgalla, Marialessia Lerede, Luca RicheldiSarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|February 7, 2006
Steroid and/or other immunosuppressive therapies in idiopathic interstitial pneumonias: have they still a role?Fabrizio Luppi, Stefania Cerri, Luca RicheldiExpert Opinion on Drug Safety|April 21, 2021
An updated safety review of the drug treatments for idiopathic pulmonary fibrosisGiacomo Sgalla, Alessia Comes, Luca RicheldiExpert Review of Respiratory Medicine|August 24, 2011
Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY programLuca Richeldi, Roland M du BoisCurrent Opinion in Pulmonary Medicine|July 15, 2022
Novel insights in fibrotic pulmonary sarcoidosisAlessia Comes, Carmelo Sofia, Luca RicheldiRespirology (Carlton, Vic.)|November 24, 2015
Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural historyGiacomo Sgalla, Alice Biffi, Luca RicheldiExpert Opinion on Biological Therapy|October 5, 2023
An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosisJacopo Simonetti, Giacomo Sgalla, Luca RicheldiThe European Respiratory Journal|December 11, 2012
Prevalence and prognosis of unclassifiable interstitial lung diseaseChristopher J Ryerson, Thomas H Urbania, Luca Richeldi, et al.Pageof 45